VIDEO: No ‘hard-to-reach’ patients in HCV, just ‘hardly reached’
Click Here to Manage Email Alerts
In this exclusive video, Joss O’Loan, MBBS, from the Hepatitis C Kombi Clinic in Brisbane, Australia, discusses two studies presented at The Digital International Liver Congress on HCV elimination programs using Epclusa.
The first study looked at the efficacy of the Epclusa (sofosbuvir/velpatasvir, Gilead Sciences) in an Australian primary care setting. Researchers found that general practitioner- and nurse-led clinics could offer care with high sustained virologic response rates.
The second study also showed that the treatment could provide high cure rates, this time among underserved patient populations, including patients experiencing mental health disorders, incarceration or homelessness in the United States, Canada and Europe.
“There’s no such thing as a hard-to-reach patient, just a hardly reached patient” O’Loan said. “These two posters really emphasize that point.”
Collapse
O’Loan J, et al. Abstract THU419. Presented at: The International Liver Congress. Aug. 27-29, 2020.
Read more about
Click Here to Manage Email Alerts